Valneva's 15-min chart shows RSI Overbought and Narrowing Bollinger Bands.
PorAinvest
martes, 14 de octubre de 2025, 1:33 pm ET1 min de lectura
VALN--
The investigation focuses on whether Valneva and its officers and/or directors have engaged in securities fraud or other unlawful business practices. The investigation was prompted by recent developments surrounding Valneva's chikungunya virus vaccine, IXCHIQ.
On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ among people 65 years of age and older. This announcement led to a significant drop in Valneva's American Depositary Receipt (ADR) price, falling $1.06 per ADR or 13.57% over four trading sessions to close at $6.75 per ADR on February 28, 2025, according to a Morningstar report.
Further, on August 22, 2025, the U.S. Food and Drug Administration (FDA) suspended the marketing application for IXCHIQ due to safety concerns. This news resulted in another substantial decline in Valneva's ADR price, falling $2.21 per ADR or 18.99% to close at $9.43 per ADR on August 25, 2025, as the Morningstar report also noted.
The RSI indicator on Valneva's 15-minute chart reached an overbought level as of October 14, 2025, at 13:30, suggesting that the stock price has risen too rapidly and exceeds the support provided by fundamental analysis. Additionally, the Bollinger Bands were narrowing, indicating a decrease in the magnitude of stock price fluctuations .
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has a distinguished history in the areas of corporate, securities, and antitrust class litigation. The firm, founded by the late Abraham L. Pomerantz, has recovered numerous multimillion-dollar damages awards on behalf of class members.
Based on the 15-minute chart for Valneva, the RSI indicator has reached an overbought level, and the Bollinger Bands are narrowing as of October 14, 2025, at 13:30. This suggests that the stock price has risen too rapidly and exceeds the support provided by fundamental analysis, with a decrease in the magnitude of stock price fluctuations.
New York, Oct. 13, 2025 – Pomerantz LLP, a renowned law firm specializing in securities class actions, has initiated an investigation into claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information.The investigation focuses on whether Valneva and its officers and/or directors have engaged in securities fraud or other unlawful business practices. The investigation was prompted by recent developments surrounding Valneva's chikungunya virus vaccine, IXCHIQ.
On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ among people 65 years of age and older. This announcement led to a significant drop in Valneva's American Depositary Receipt (ADR) price, falling $1.06 per ADR or 13.57% over four trading sessions to close at $6.75 per ADR on February 28, 2025, according to a Morningstar report.
Further, on August 22, 2025, the U.S. Food and Drug Administration (FDA) suspended the marketing application for IXCHIQ due to safety concerns. This news resulted in another substantial decline in Valneva's ADR price, falling $2.21 per ADR or 18.99% to close at $9.43 per ADR on August 25, 2025, as the Morningstar report also noted.
The RSI indicator on Valneva's 15-minute chart reached an overbought level as of October 14, 2025, at 13:30, suggesting that the stock price has risen too rapidly and exceeds the support provided by fundamental analysis. Additionally, the Bollinger Bands were narrowing, indicating a decrease in the magnitude of stock price fluctuations .
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has a distinguished history in the areas of corporate, securities, and antitrust class litigation. The firm, founded by the late Abraham L. Pomerantz, has recovered numerous multimillion-dollar damages awards on behalf of class members.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios